Current trends in targeted therapies for glioblastoma multiforme - Wikidata - awgldk - TriplyDB

Current trends in targeted therapies for glioblastoma multiforme

Current trends in targeted therapies for glioblastoma multiforme

http://www.wikidata.org/entity/Q35864226

about

A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Integration of pathway structure information into a reweighted partial Cox regression approach for survival analysis on high-dimensional gene expression data.A tree shrew glioblastoma model recapitulates features of human glioblastoma Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4 Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.Tumor treating fields: a new frontier in cancer therapy.Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.N-(2-hydroxyphenyl)acetamide (NA-2) and Temozolomide synergistically induce apoptosis in human glioblastoma cell line U87.An integrated mRNA and microRNA expression signature for glioblastoma multiforme prognosis.The challenges and the promise of molecular targeted therapy in malignant gliomas.Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells.A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes.Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.Signal transduction molecule patterns indicating potential glioblastoma therapy approaches.Multivoxel magnetic resonance spectroscopy identifies enriched foci of cancer stem-like cells in high-grade gliomas.3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines.Autoimmunity as a double agent in tumor killing and cancer promotion.Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes.Molecular targets in glioblastoma.MicroR-545 mediates colorectal cancer cells proliferation through up-regulating epidermal growth factor receptor expression in HOTAIR long non-coding RNA dependent.miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway.Spatiotemporal genomic architecture informs precision oncology in glioblastoma.Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis.Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.Immunoexcitatory mechanisms in glioma proliferation, invasion and occasional metastasis.Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas.Decoding the cancer stem cell hypothesis in glioblastoma.Glioblastoma multiforme from diagnosis to death: a prospective, hospital-based, cohort, pilot feasibility study of patient reported symptoms and needs.ATP7B expression in human glioblastoma is related to temozolomide resistance.

P2860

Q24633772-A712AD72-994D-4B40-AB02-3D9727CD85BC Q27011423-F6071121-D74E-4A5A-B8E7-DFB486F2FDB3 Q27333552-9AE21A3C-5A88-4515-9EDB-AD83689795D9 Q28067135-2F457301-A78E-481C-B84A-C287EF87C08D Q30412393-6ACEA488-542E-4C7C-B243-E7DA1E64ABC7 Q30936687-2AAC9E23-609A-4DC4-ABD9-DFBAB7696872 Q33566729-968467C6-5AC6-4944-BB0B-156CEC50EA84 Q33618844-7D8C2ED9-D841-4A17-8B5C-AA00A133230D Q33829265-BE42F5D9-DCEA-483A-BF1F-69B1654415EB Q34097238-6B3EA828-9753-4777-AF90-C962CA8E6C46 Q34251033-CE12FEA5-DEAF-43E0-88D4-DFCCFC773E3E Q34343822-D4F196B4-8E6E-4C64-9359-844051393691 Q34657670-8D50031C-B419-4EEA-BF8C-DFCD523D47B8 Q35056313-E8B766BD-4AE8-4D61-B8D5-D215382F832B Q35175490-0819D6DA-DA0C-496F-90A2-75050DDCDC1B Q35214534-36824205-E887-47B3-B075-55C77AF0929E Q36200482-2A21E472-37D6-4E08-85CC-241E138CF4B5 Q36524716-10627F3B-68E8-463F-BE59-7013FF1DC692 Q36545707-13884A22-6BF6-4447-A599-41845D06A512 Q36554387-6C47DD6A-6FC8-4B54-A49D-6AAFE4F6B06C Q36729480-AA45F102-1EA9-414D-B070-EDEFF280BD85 Q37077653-A054DD89-C0C9-4FB9-A2C9-9185B0DEC857 Q37168749-D6A7035F-1D3A-4524-945D-EE242CBA8463 Q37360227-42C3C2CA-54A4-44BF-AEE1-B5E27390827D Q37573471-58FE9FCC-5496-4BE5-8168-09BE098FA38F Q37587640-BEEACAAB-879B-4925-91B9-CB49EB9B042C Q37642271-BCE93741-EFA6-407F-89EA-8C5C8BC442B9 Q37734374-644FE8AE-526D-4271-92D3-6786C2D7D47E Q38465854-4163FE7F-B09C-4BFC-A905-F9F0F1578A16 Q38863623-5CB3005D-25AC-45D6-8E21-1AC1CD9C3318 Q38900748-28348789-03ED-41C6-B832-2B3D1B8C6EAB Q38927317-013148A0-79A7-4975-8AD9-1808C27B573E Q39152200-A6D9FF3B-4513-4E80-B73F-AE393BBD8494 Q39592757-04A982CD-BDD4-4CED-B8C1-BDECE270C79C Q41061766-31B4408A-BD49-45DC-A46D-A6F7D3618697 Q41541275-0E9731B3-43DE-4BAA-A66C-13C10BEB899C Q41562532-E9727AF4-69FE-43A3-AFDD-C0C1AB3BC3B6 Q42115145-CB1332AA-2FCC-41A9-B3EA-06DE4EA0465D Q45173127-8E6AD6CC-33F4-4CFA-BD8C-CA702D4CEA65 Q47130958-9A86E14D-4253-4E1F-99B3-DEF0AF99F9E9

P2860

Current trends in targeted therapies for glioblastoma multiforme

http://www.wikidata.org/entity/Q35864226

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Current trends in targeted therapies for glioblastoma multiforme

@ast

Current trends in targeted therapies for glioblastoma multiforme

@en

type

label

Current trends in targeted therapies for glioblastoma multiforme

@ast

Current trends in targeted therapies for glioblastoma multiforme

@en

prefLabel

Current trends in targeted therapies for glioblastoma multiforme

@ast

Current trends in targeted therapies for glioblastoma multiforme

@en

P1433

Q35864226-9FEF1B61-6842-4476-8FDE-3F3C70AD5EE9

P1476

Q35864226-2AFFD38C-F943-4529-87A1-12542C980F94

P2093

Q35864226-119AE920-35F7-4341-B630-6AEB2D50EFEC

Q35864226-16D522D4-75D4-4C3B-BB2D-D4E834B12665

Q35864226-BF44351D-5056-4F11-A6D8-96A33BA5AD71

P2860

Q35864226-02771318-E50B-4DD5-A0AB-BA28AC569CC7

Q35864226-0457EE60-C3A8-4B0D-847C-95D0FA6E0F2A

Q35864226-04F53176-AE2D-4307-923B-F1F8D696783C

Q35864226-05FE2187-6835-44E3-BD04-7FD1B5CCCE6B

Q35864226-060F5E81-D847-4409-A52C-1E3D4304B9D8

Q35864226-0F3FE592-B712-4BFD-AC10-D423E5B10FEE

Q35864226-0F55652A-6AD2-4A85-9DDC-EAB333262071

Q35864226-0FBF3C3D-D297-4357-8068-B6796CBE7E5D

Q35864226-130FC3FF-F065-4F8F-9011-C32C225965E7

Q35864226-1745AFC0-DBD3-40E4-8714-04AF015C00E7

P304

Q35864226-6FDB8EA5-810C-45EA-8D82-BAEADFC16F4D

P31

Q35864226-18CBD9EB-24DA-4DEF-BC68-9F7B60A3351E

P356

Q35864226-DA241375-08DA-421F-8E43-8B0F1ECF59BA

P478

Q35864226-8666A97E-1F25-4CE3-8A1A-9723333153BB

P577

Q35864226-083B61B1-95CA-436F-BD67-F98107AB9EF7

P5875

Q35864226-1F4AACDE-2FAD-4AF4-9B12-28BD0E50F8F9

P698

Q35864226-8E1FF9FD-332B-4CF6-851F-242F54517092

P932

Q35864226-DE2F5689-F35B-47EE-AAC2-3BB8C11DCC81

P356

P1433

Neurology Research International

P1476

Current trends in targeted therapies for glioblastoma multiforme

@en

P2093

Atsushi Natsume

http://www.w3.org/2001/XMLSchema#string

Fumiharu Ohka

http://www.w3.org/2001/XMLSchema#string

Toshihiko Wakabayashi

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

An integrated genomic analysis of human glioblastoma multiforme

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Identification of human brain tumour initiating cells

IL-13 effector functions

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

P304

878425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/878425

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224822270

http://www.w3.org/2001/XMLSchema#string

P698

22530127

http://www.w3.org/2001/XMLSchema#string

P932

3317017

http://www.w3.org/2001/XMLSchema#string